NCT06456658

Brief Summary

Statins reduce cardiovascular events and mortality, but only 30% of eligible primary care patients nationally are on statins. Clinical decision support (CDS) interventions in the electronic health record (EHR) can deliver education to providers and increase adherence to guideline recommendations via many potential forms of delivery. Interruptive alerts are an effective form of CDS but disrupt clinician workflow and increase alert fatigue in an age of clinician burnout and frustration with the EHR. Non-interruptive reminders are proposed as an alternative method of delivering CDS; however, they require active pursuit by the provider, and their effectiveness compared to interruptive alerts has not been rigorously studied. The investigators propose a randomized trial comparing the effect of interruptive vs. non-interruptive reminders displayed to clinicians to increase statin prescribing in primary care clinics.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
3,332

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Aug 2024

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 7, 2024

Completed
6 days until next milestone

First Posted

Study publicly available on registry

June 13, 2024

Completed
2 months until next milestone

Study Start

First participant enrolled

August 14, 2024

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 20, 2024

Completed
12 months until next milestone

Study Completion

Last participant's last visit for all outcomes

November 19, 2025

Completed
Last Updated

December 16, 2025

Status Verified

December 1, 2025

Enrollment Period

3 months

First QC Date

June 7, 2024

Last Update Submit

December 8, 2025

Conditions

Outcome Measures

Primary Outcomes (1)

  • Statin prescription within 24 hours

    Statin prescription within 24 hours post-enrollment (either interruptive, non-interruptive, or silent/hidden reminder).

    Baseline to 24-hours

Secondary Outcomes (2)

  • Statin prescription within 12 months

    Baseline to 12 months

  • Low density lipoprotein-cholesterol (LDL-C) level

    Baseline to 12 months

Study Arms (3)

Interruptive Reminder Group

ACTIVE COMPARATOR

Providers will receive education via a pop-up alert at the time that the chart is opened for eligible patient visits assigned to the interruptive reminder group.

Other: Interruptive Reminder

Non-Interruptive Reminder Group

ACTIVE COMPARATOR

Providers will be able to seek out education at their own initiative via an on-demand reminder within a section of the chart for eligible patient visits assigned to the non-interruptive reminder group.

Other: Non-interruptive Reminder

No Reminder Group

ACTIVE COMPARATOR

No alert recommending a statin will be displayed/available to the provider. The system will record eligibility through triggering a "silent" reminder, which is not displayed to the clinician and exists solely for data collection purposes.

Other: No Reminder

Interventions

The reminder will have the same format as the interruptive reminder group, but it will not be displayed unless providers seek out the education at their own initiative. The reminder will alert clinicians that a statin is recommended for the patient and list the reasons the statin is indicated. It will give the clinicians a defaulted option for statin prescription as well as alternatives. If the clinician accepts the alert, an order for a statin will be placed in their "shopping cart" for convenience, and the order can be signed to prescribe the medication. If the clinician does not wish to prescribe a statin from the reminder, they can choose an acknowledgement reason.

Non-Interruptive Reminder Group

No reminder recommending a statin will be displayed/available to the provider.

No Reminder Group

The reminder will display at the time the chart is opened for eligible patient visits and alert clinicians that a statin is recommended for the patient and list the reasons the statin is indicated. It will give the clinicians a defaulted option for statin prescription as well as alternatives. If the clinician accepts the alert, an order for a statin will be placed in their "shopping cart" for convenience, and the order can be signed to prescribe the medication. If the clinician does not wish to prescribe a statin from the reminder, they can choose an acknowledgement reason.

Interruptive Reminder Group

Eligibility Criteria

Age18 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients between the ages of 18 and 75
  • Seen in primary care visit within Vanderbilt University Medical Center
  • Eligible for statin therapy due to 1) Atherosclerotic cardiovascular disease (ASCVD) 10- year risk greater than or equal to 10%, 2) Type 1 or 2 diabetes and aged 40 years or older, or 3) ASCVD diagnosis

You may not qualify if:

  • Already on statin, ezetimibe, bempedoic acid, or PCSK9 inhibitor
  • Last low-density lipoprotein cholesterol (LDL-C) less than 100 mg/dL
  • Pregnant or lactating
  • Palliative care
  • Statin allergy or adverse effect of statin
  • Rhabdomyolysis
  • Statin contraindicated due to liver disease, defined as 1) Decompensated liver disease, 2) AST or ALT greater than 5 times the upper limit of normal, or 3) Total bilirubin greater than 1.5 mg/dL
  • Statin contraindicated due to kidney disease, defined as 1) Dialysis or 2) Estimated glomerular filtration rate less than 15 ml/min/1.73m\^2
  • Has had coronary calcium computerized tomography
  • Less than 3 months since lipid panel resulted
  • Acute visit

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Vanderbilt University Medical Center

Nashville, Tennessee, 37203, United States

Location

Related Publications (1)

  • Wright AP, Choi L, Nairon KG, Gatto CL, Dear ML, Van Winkle G, Lagalante S, Neal EB, Wright A, Rice TW; Vanderbilt Center for Learning Healthcare. Interruptive versus Non-Interruptive Reminders for Statin tHerApy in Primary Care (INIRSHA-PC): protocol and statistical analysis plan for a randomised clinical trial. BMJ Open. 2026 Jan 28;16(1):e108123. doi: 10.1136/bmjopen-2025-108123.

MeSH Terms

Conditions

Hypercholesterolemia

Condition Hierarchy (Ancestors)

HyperlipidemiasDyslipidemiasLipid Metabolism DisordersMetabolic DiseasesNutritional and Metabolic Diseases

Study Officials

  • Aileen P Wright, MD, MS

    Vanderbilt University Medical Center

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
INVESTIGATOR
Purpose
HEALTH SERVICES RESEARCH
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator, Instructor

Study Record Dates

First Submitted

June 7, 2024

First Posted

June 13, 2024

Study Start

August 14, 2024

Primary Completion

November 20, 2024

Study Completion

November 19, 2025

Last Updated

December 16, 2025

Record last verified: 2025-12

Data Sharing

IPD Sharing
Will share

Individual participant data that underlie the results reported will be made available (including data dictionaries) after de-identification.

Shared Documents
STUDY PROTOCOL, SAP, ANALYTIC CODE
Time Frame
The data will become available 3 months following publication of outcomes and will remain available for at least 5 years.
Access Criteria
Data will be made accessible to researchers who provide a methodologically sound proposal that has been approved by the Vanderbilt Institutional Review Board and the study executive committee.

Locations